Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer

Abstract Background Neoadjuvant anti‐programmed cell death 1 (PD‐1) immunochemotherapy has shown promising efficiency in the treatment of early‐stage non‐small‐cell lung cancer (NSCLC), but it has not consistently yielded durable responses. Biomarkers for the prediction of efficacy are warranted. Me...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ailing Cao, Yaobin Lin, Shaoxing Guan, Youhao Chen, Wenyu Zhai, Yuheng Zhou, Shoucheng Feng, Yanping Guan, Yiyu Zhang, Min Huang, Xueding Wang, Hao Long
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2026-01-01
Saila:	Clinical and Translational Medicine
Gaiak:	gut microbiota metabolomics neoadjuvant NSCLC PD‐1
Sarrera elektronikoa:	https://doi.org/10.1002/ctm2.70579
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!